{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:13Z","timestamp":1794047473492,"version":"4.8.0"},"reference-count":17,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The open reading frame 8 (ORF8) protein, encoded by the SARS-CoV-2 virus after infection, stimulates monocytes\/macrophages to produce pro-inflammatory cytokines. We hypothesized that a positive ex vivo monocyte response to ORF8 protein pre-COVID-19 would be associated with subsequent severe Coronavirus disease 2019 (COVID-19). We tested ORF8 ex vivo on peripheral blood mononuclear cells from 26 anonymous healthy blood donors and measured intracellular cytokine\/ chemokine levels in monocytes by flow cytometry. The percentage of positive monocyte staining in the sample and change in mean fluorescence intensity (\u0394MFI) after ORF8 were used to calculate the adjusted MFI for each cytokine. We then tested pre-COVID-19 peripheral blood mononuclear cell samples from 60 chronic lymphocytic leukemia (CLL) patients who subsequently developed COVID-19 infection. Severe COVID-19 was defined as hospitalization due to COVID-19. In the 26 normal donor samples, the adjusted MFI for interleukin (IL)-1\u03b2, IL-6, IL-8, and CCL-2 were significantly different with ORF8 stimulation versus controls. We next analyzed monocytes from pre-COVID-19 PBMC samples from 60 CLL patients. The adjusted MFI to ORF8 stimulation of monocyte intracellular IL-1\u03b2 was associated with severe COVID-19 and a reactive ORF8 monocyte response was defined as an IL-1\u03b2 adjusted MFI \u22650.18 (sensitivity 67%, specificity 75%). The median time to hospitalization after infection in CLL patients with a reactive ORF8 response was 12 days versus not reached for patients with a non-reactive ORF8 response with a hazard ratio of 7.7 (95% confidence interval: 2.4-132; P=0.005). These results provide new insight on the monocyte inflammatory response to virus with implications in a broad range of disorders involving monocytes.<\/jats:p>","DOI":"10.3324\/haematol.2023.284617","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T03:06:43Z","timestamp":1713928003000},"page":"2884-2892","source":"Crossref","is-referenced-by-count":0,"title":["Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Gordon J.","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Gwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K","family":"Manske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Witter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari G","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"65718","doi-asserted-by":"crossref","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-1643.","DOI":"10.1038\/s41591-020-1051-9"},{"key":"65719","doi-asserted-by":"crossref","unstructured":"Vanderbeke L, Van Mol P, Van Herck Y. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021; 12(1):4117.","DOI":"10.1038\/s41467-021-24360-w"},{"key":"65720","doi-asserted-by":"crossref","unstructured":"Sergi CM, Chiu B. Targeting NLRP3 inflammasome in an animal model for Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Med Virol. 2021; 93(2):669-670.","DOI":"10.1002\/jmv.26461"},{"key":"65721","doi-asserted-by":"crossref","unstructured":"Wu X, Manske MK, Ruan GJ. Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19. iScience. 2023; 26(6):106929.","DOI":"10.1016\/j.isci.2023.106929"},{"key":"65722","doi-asserted-by":"crossref","unstructured":"Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001; 107(12):1529-1536.","DOI":"10.1172\/JCI12568"},{"key":"65723","doi-asserted-by":"crossref","unstructured":"Dietz AB, Bulur PA, Emery RL. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006; 46(12):2083-2089.","DOI":"10.1111\/j.1537-2995.2006.01033.x"},{"key":"65724","doi-asserted-by":"crossref","unstructured":"Mizrahi O, Ish Shalom E, Baniyash M, Klieger Y. Quantitative flow cytometry: concerns and recommendations in clinic and research. Cytometry B Clin Cytom. 2018; 94(2):211-218.","DOI":"10.1002\/cyto.b.21515"},{"key":"65725","doi-asserted-by":"crossref","unstructured":"Manso BA, Medina KL. Standardized flow-cytometry-based protocol to simultaneously measure transcription factor levels. STAR Protoc. 2021; 2(2):100485.","DOI":"10.1016\/j.xpro.2021.100485"},{"key":"65726","doi-asserted-by":"crossref","unstructured":"Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47(4):458-472.","DOI":"10.1002\/bimj.200410135"},{"key":"65727","doi-asserted-by":"crossref","unstructured":"Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021; 93(1):250-256.","DOI":"10.1002\/jmv.26232"},{"key":"65728","doi-asserted-by":"crossref","unstructured":"Junqueira C, Crespo A, Ranjbar S. FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022; 606(7914):576-584.","DOI":"10.1038\/s41586-022-04702-4"},{"key":"65729","doi-asserted-by":"crossref","unstructured":"Bektas M, Ozdemir G. Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy. Clin Immunol. 2022; 236:108936.","DOI":"10.1016\/j.clim.2022.108936"},{"key":"65730","doi-asserted-by":"crossref","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019; 20(13):3328.","DOI":"10.3390\/ijms20133328"},{"key":"65731","doi-asserted-by":"crossref","unstructured":"Krueger J, Ray A, Tamm I, Sehgal PB. Expression and function of interleukin-6 in epithelial cells. J Cell Biochem. 1991; 45(4):327-334.","DOI":"10.1002\/jcb.240450404"},{"key":"65732","doi-asserted-by":"crossref","unstructured":"Mato AR, Roeker LE, Lamanna N. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020; 136(10):1134-1143.","DOI":"10.1182\/blood.2020006965"},{"key":"65733","doi-asserted-by":"crossref","unstructured":"Scarfo L, Chatzikonstantinou T, Rigolin GM. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020; 34(9):2354-2363.","DOI":"10.1038\/s41375-020-0959-x"},{"key":"65734","doi-asserted-by":"crossref","unstructured":"Zeng J, Xie X, Feng XL. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. EBioMedicine. 2022; 75:103803.","DOI":"10.1016\/j.ebiom.2021.103803"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284617\/76914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284617\/77428","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11563\/76914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:17Z","timestamp":1794045977000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284617","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}